Key result
IV cangrelor for acute neuroendovascular procedures was feasible, with 1 thrombotic event, 3 bleeding events, and 75% of discharged patients achieving a good 90-day functional outcome.
Why the study?
Dual antiplatelet therapy in the acute phase of neuroendovascular procedures can be challenging, prompting evaluation of the feasibility and safety of intravenous cangrelor.
Is intravenous cangrelor safe and feasible as an antiplatelet treatment during acute neuroendovascular surgery procedures?
Design
Retrospective database analysis
Follow-up
90 days
Authors
Loading...
May support cangrelor as DAP alternative in acute neurointerventions; leaves open need for prospective trials before practice change.
Observational (n=10)
Is intravenous cangrelor safe and feasible as an antiplatelet treatment during acute neuroendovascular surgery procedures?
Intravenous cangrelor is a feasible antiplatelet treatment option for acute neuroendovascular procedures, though it carries inherent risks of bleeding and thrombosis in this critically ill population.
Linfante et al. (2020) conducted an observational in Acute neuroendovascular surgery procedures (n=10). IV cangrelor was evaluated on Feasibility and safety (morbidity, mortality, thromboembolic events, hemorrhages, and 90-day outcomes). IV cangrelor for acute neuroendovascular procedures was feasible, with 1 thrombotic event, 3 bleeding events, and 75% of discharged patients achieving a good 90-day functional outcome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: